• 5 Posts
  • 152 Comments
Joined 4 months ago
cake
Cake day: February 11th, 2026

help-circle









  • Ahhhh fair play. I have a lot of freedom since I’m paying out of pocket for my own use. I have a pretty beefy rig for running local, but it’s not beefy enough to run deepseek pro and the like 😬 so, I have a bunch of subscriptions to try out a bunch of different models and see what works best in my workflow. I also have a problem with making alts in games, which seems like it rhymes 🤔

    Been pretty impressed with glm5.1 too, before deepseek-v4 came out, but you’d be amazed what even a smaller older coding model can do with the right config and a little proactive context management. I really hope this trend of smaller, better models for local agentic use continues.






  • Personal ones. If I had to distill it here, I require that my prose be varied but sensible (e.g. breaks the rules for readability, never egregiously), with no formula, no waffle words, and no meaningless sentences. Tropes can be fine but only used sparingly, naturally, and absolutely not always in the same place. Reading level should be collegiate, but not doctoral, and industry terms should be defined on first use. These are stylistic questions shaped by years of reading professional authors and no AI has any idea how to do that out of the box. Reading what most people put out with AI, I can see the patterns like repeating textures, and it grates on my optic nerves.

    I’m making progress on that with mine, but it’s a tough problem. Needs manual tweaking even after multiple rounds of automated revision.






  • Misleading headline. What they actually demonstrated is reversing amyloid accumulation and the cognitive deficits in a transgenic mouse whose pathology is essentially just amyloid accumulation. Calling that “reversing Alzheimer’s” treats amyloid buildup and the disease as the same thing, which is exactly the conflation the amyloid hypothesis has been criticised for over the last decade.

    Alzheimer’s in humans is amyloid + tau tangles + neuroinflammation + vascular dysfunction + actual neurodegeneration (entorhinal and hippocampal neurons dying, brain volume measurably dropping on MRI). Tau burden correlates with cognitive decline far better than amyloid does. The IBEC paper addresses one of those layers, the upstream-ish one, in a model that doesn’t reproduce most of the others. Fixing a cause in a young system before damage has accumulated is just not the same operation as fixing an established disease in an old human cortex that’s already lost the cells.

    The human translation data backs this up. Lecanemab clears plaques and slows cognitive decline by about 27% over 18 months. Donanemab clears around 76% of plaques and slows decline by ~35% in early AD. In both trials both arms still declined, treatment just declined a bit more slowly. Northwestern’s Mesulam Institute puts it bluntly: “These medications do not reverse existing disease or stop the progression.” So removing amyloid in a system that already has the full human pathology bends the curve, it doesn’t undo anything.

    What the IBEC team has here is a genuinely interesting result for the cerebrovascular angle, where BBB dysfunction and glymphatic clearance failure are upstream of plaque accumulation rather than a downstream consequence. The LRP1 transport mechanism and the multivalent ligand design are clever and well-grounded. The fair claim is “we improved amyloid clearance and rescued behavioural deficits in an amyloid-overexpressing mouse by targeting BBB transport.” That’s a real contribution. “Reversed Alzheimer’s” sells the mechanism by overstating what it did, and it sets up the same disappointment cycle the field has been through with every other anti-amyloid intervention that worked great in mice.

    Original paper, for anyone wanting the actual data: https://doi.org/10.1038/s41392-025-02426-1